Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816157 | 0.89 | LMNA (0.54) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL27151384 | 0.89 | LMNA (0.54) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL323088 | 0.87 | SMN1; SMN2 (0.53) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL2778567 | 0.87 | SMN1; SMN2 (0.53) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL30367858 | 0.86 | LMNA (0.51) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL16653986 | 0.86 | LMNA (0.51) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL29838431 | 0.86 | LMNA (0.46) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL29838554 | 0.86 | LMNA (0.46) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL31554325 | 0.84 | POLB (0.50) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 | |
| SCHEMBL1404236 | 0.84 | POLB (0.50) | LMNAPOLBSMN1; SMN2ALDH1A1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158872-A1 | 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2022198905-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| EP-4055013-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2022-09-14 | — | — | EP | disclosed |
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020162471-A1 | PYRIDONE DERIVATIVE | マルホ株式会社 | 2020-08-13 | — | — | WO | disclosed |
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-01-30 | — | — | US | disclosed |
| EP-3215509-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073891-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-7528150-B2 | Urea derivatives having vanilloid receptor antagonist activity | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-20060178397-A1 | Urea derivatives having vanilloid receptor antagonist activity | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| EP-1608640-A2 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078101-A2 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178397-A1 | Urea derivatives having vanilloid receptor antagonist activity | UTS2R, TRPV1, TACR1 | LMNA 3122/4885POLB 3286/4885SMN1; SMN2 4634/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | LMNA 2364/4885POLB 47/4885SMN1; SMN2 30/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | LMNA 977/4885POLB 1874/4885SMN1; SMN2 4406/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | LMNA 2364/4885POLB 47/4885SMN1; SMN2 30/4885 |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | LMNA 2364/4885POLB 47/4885SMN1; SMN2 30/4885 |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | LMNA 2364/4885POLB 47/4885SMN1; SMN2 30/4885 |
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | CACNA1I, CACNA1G, CACNA1H | LMNA 3453/4885POLB 4507/4885SMN1; SMN2 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.